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SYSTEMATIC REVIEW
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diseases in primary care: a systematic review of quality indicators
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aDepartment of Clinical Microbiology, Herlev University Hospital, Herlev, Denmark; bDepartment of Public Health, Research Unit for
General Practice and Section of General Practice, University of Copenhagen, Copenhagen, Denmark; cCentre for Research in Evidence-
Based Practice, Bond University, Robina, Australia; dDepartment of Public Health, Research Unit of General Practice, University of
Southern Denmark, Odense, Denmark
ABSTRACT
Objective: To identify existing quality indicators (QIs) for diagnosis and antibiotic treatment of
patients with infectious diseases in primary care.
Design: A systematic literature search was performed in PubMed and EMBASE. We included stud-
ies with a description of the development of QIs for diagnosis and antibiotic use in patients with
infectious diseases in primary care. We extracted information about (1) type of infection; (2) target
for quality assessment; (3) methodology used for developing the QIs; and (4) whether the QIs
were developed for a national or international application. The QIs were organised into three cat-
egories: (1) QIs focusing on the diagnostic process; (2) QIs focusing on the decision to prescribe
antibiotics; and (3) QIs concerning the choice of antibiotics.
Results: Eleven studies were included in this review and a total of 130 QIs were identified. The
majority (72%) of the QIs were focusing on choice of antibiotics, 22% concerned the decision to
prescribe antibiotics, and few (6%) concerned the diagnostic process. Most QIs were either
related to respiratory tract infections or not related to any type of infection. A consensus method
(mainly the Delphi technique), based on either a literature study or national guidelines, was used
for the development of QIs in all of the studies.
Conclusions: The small number of existing QIs predominantly focuses on the choice of antibiot-
ics and is often drug-specific. There is a remarkable lack of diagnostic QIs. Future development of
new QIs, especially disease-specific QIs concerning the diagnostic process, is needed.
KEY POINTS
 In order to improve the use of antibiotics in primary care, measurable instruments, such as
quality indicators, are needed to assess the quality of care being provided.
 A total of 11 studies were found, including 130 quality indicators for diagnosis and antibiotic
treatment of infectious diseases in primary care.
 The majority of the identified quality indicators were focusing on the choice of antibiotics and
only a few concerned the diagnostic process.
 All quality indicators were developed by means of a consensus method and were often based
on literature studies or guidelines.
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Introduction
According to WHO, antimicrobial resistance (AMR) is
one of the most important public health problems in
the world.[1] Several studies have shown that AMR is
closely related to overuse and inappropriate choice of
antibiotics.[2,3] Particularly, inappropriate use of broad-
spectrum antibiotics is an important problem, because
it leads to a selection of resistant strains.[4] During the
last decades, the use of broad-spectrum antibiotics
has increased worldwide, and in most countries, an
increased prevalence of resistant strains has been
observed.[1] About 25,000 persons in Europe die every
year as a direct consequence of infections due to
resistant bacteria.[5] A recent review on AMR reported
that unless action is taken to address this huge global
problem, by 2050 an additional 10 million lives a year
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worldwide will be lost, more than the number of peo-
ple currently dying from cancer.[6] Consequently, it is
of greatest importance to reduce the inappropriate use
of antibiotics and preserve treatment only for those
who will benefit the most.[1] Since the majority of anti-
biotic prescriptions are issued in primary care, initia-
tives to improve the quality of antibiotic prescribing
should include general practitioners (GPs).[7]
During the past decades, there has been an exten-
sive focus on improving the quality of care in general
practice.[8,9] Most of this activity has been targeted
chronic diseases, such as diabetes and cardiovascular
diseases,[10] but there has only been a minor focus on
quality assessment in patients with infectious diseases.
Of infectious diseases, acute respiratory tract infec-
tions (RTIs) are among the most frequent reasons for
encounter in general practice,[11] and studies have
shown that antibiotics are prescribed for more than
50% of patients with RTIs.[12,13] However, the majority
of RTIs are caused by virus, and in most cases, antibiot-
ics provides little, if any, benefit.[14–16]
In order to improve the use of antibiotics in primary
care, valid instruments are necessary to assess the
quality of care provided. Quality indicators (QIs) allow
benchmarking by comparisons between practices or
even between different municipalities or countries, and
this has proven to be an important stimulus for quality
improvement.[17] A quality indicator is defined as a
specific and measurable element of practice that can
be used to assess the quality of care,[18] and it is typ-
ically calculated as a ratio (e.g. number of antibiotic
prescriptions related to the number of consultations).
Usually, QIs are developed based on scientific evidence
combined with consensus methods implemented by
professionals in the field. They are often derived from
retrospective reviews of medical records and can
assess both appropriate and inappropriate clinical
investigation or treatment. QIs are used to generate a
reflection and debate about quality of care; hence, it is
an indicator, rather than a definitive judgment of
quality.[18,19]
In order to evaluate the quality of care in patients
with infections, it is important to assess the clinical cri-
teria that were used to establish the diagnosis, the cri-
teria for the decision to prescribe antibiotics and the
criteria for the choice of antibiotics. Hence, three differ-
ent aspects of the clinical process have to be taken
into account:
1. Assessment of the diagnostic process leading to
the diagnosis
2. Assessment of the decision to prescribe antibiotics
3. Assessment of the choice of antibiotics
The aim of this study was to identify existing QIs for
diagnosis and antibiotic treatment of patients with
infectious diseases in primary care.
Materials and methods
Literature search
A systematic search was performed to identify QIs for
diagnosis and antibiotic use in patients with infec-
tious diseases in primary care. Peer-reviewed articles
published from 1974 to November 2014 in English,
Danish and Swedish were identified from PubMed
and EMBASE. We conducted a search based on the
following keywords: ‘‘antibiotic’’, ‘‘diagnosis’’, and
‘‘infection’’, ‘‘treatment’’, and ‘‘infection’’, ‘‘respiratory
infection’’, ‘‘general practice’’, ‘‘primary care’’, ‘‘out-
patient care’’, ‘‘quality indicator’’, and the following
MeSH terms: ‘‘general practice’’, ‘‘general practi-
tioners’’, ‘‘primary health care’’, ‘‘ambulatory care’’,
‘‘outcome and process assessment’’, ‘‘benchmarking’’,
‘‘quality of health care’’, ‘‘total quality management’’,
‘‘quality improvement’’, ‘‘quality indicators’’, ‘‘guideline
adherence’’ ‘‘infection/diagnosis’’, ‘‘infections/diagnostic
use’’, ‘‘infection/drug therapy’’, ‘‘infection/therapeutic
use’’, ‘‘infection/therapy’’, and ‘‘antibacterial agents’’.
A complete search string is available from the authors
on request.
Selection of articles
Studies including a description of the development of
QIs for diagnosis and antibiotic use in patients with
infectious diseases in primary care were included. A
study was excluded if it only reported on (1) QIs for
hospital care; (2) guidelines for the treatment of infec-
tious diseases; (3) application of already existing quality
indicators; or (4) quality indicators for gastrointestinal
infections, HIV infections, tuberculosis or unspecific
symptoms (e.g. fever). In addition, a Google search was
performed using the following keywords: ‘‘quality indi-
cator’’, ‘‘antibiotic’’, and ‘‘primary care’’. This search did
not retrieve any additional studies. We excluded
unpublished articles and non-peer-reviewed reports
(e.g. conference proceedings, technical papers,
abstracts).
In order to describe and compare the identified QIs
we extracted information about
(1) type of infection; (2) target for quality assess-
ment; (3) methodology used; and (4) whether the QIs
were developed for a national or international
application.
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE 259
The QIs were organised into three categories:
1. QIs focusing on the diagnostic process
2. QIs focusing on the decision to prescribe
antibiotics
3. QIs concerning the choice of antibiotics
The review is reported according to the PRISMA
statement.[20]
Results
Search results and study characteristics
The literature search identified 1787 potential studies.
Another seven studies meeting the criteria for inclusion
were identified after searching references of retrieved
papers. After adjusting for duplicates, 1752 remained.
A total of 1408 was excluded by title and 238 after
reading the abstract. Fifteen were excluded based on
language (Spanish, French, Hungarian, and German).
A total of 91 articles were read in full text, and 80 of
them were excluded because they either: did not use
QIs to assess quality of care (n¼ 12); did not report on
QIs for infectious diseases (n¼ 6); only had a descrip-
tion of methods for development of QIs (n¼ 5); only
concerned QIs for use in hospital settings (n¼ 4); only
dealt with quality improvement of antibiotic use in
general (n¼ 25); were conference abstracts (n¼ 6);
described the application of existing QIs (n¼ 21) or
developed standards for existing QIs (n¼ 1). The selec-
tion process resulted in a total of 11 studies fulfilling
the criteria for the synthesis of this review (Figure 1).
Quality indicators for infectious diseases
A total of 130 QIs for diagnosis and antibiotic treat-
ment of infectious diseases were identified; seven (6%)
focused on the diagnostic process, 29 (22%) on the
decision to prescribe antibiotics, and 94 (72%) QIs
focused on the choice of antibiotics (Table 1).
Sixty-eight quality indicators concerned RTIs; 15 uro-
genital infections (six urinary tract infections and nine
Figure 1. Flow diagram summary of selection process.
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sexually transmitted diseases); three skin infections,
two eye infections, and finally, 42 QIs were not related
to a specific type of infection. Seven QIs focused on
the quality of the diagnostic process by measuring the
proportion of patients having a specific clinical investi-
gation before establishing the diagnosis. All seven indi-
cators concerned sexually transmitted diseases and
were derived from one study.[21]
QIs focusing on the decision to prescribe antibiotics
are presented in Table 2. The majority of these QIs
concerned RTIs and, in general, they assessed the pro-
portion of patients with a specific infection that were
treated with antibiotics. Some QIs measured the pro-
portion of antibiotic use in subgroups specified by age
(e.g. children <2 years with acute otitis media), specific
symptoms (e.g. patients with COPD not fulfilling all the
Anthonisen criteria), duration of symptoms (e.g.
patients with less than three days of symptoms of
acute otitis media), or the result of point-of-care tests
(patients with tonsillitis and a positive Strep A test or
patients with lower RTIs and a C-reactive protein
(CRP)< 20mg/l). One indicator measured seasonal vari-
ation in antibiotic use by calculating the consumption
in winter quarters compared with summer quarters.
The majority of QIs focusing on the decision to pre-
scribe antibiotics were primarily designed to assess
overuse of antibiotics; hence, a low value (e.g. a low
percentage of patients treated with antibiotics) was
associated with a high quality of antibiotic prescribing.
An example of such a quality indicator is the propor-
tion of patients >2 years old with acute otitis media
with less than three days of symptoms treated with
antibiotics (Table 2). A small group of QIs were
designed to assess if patients with infectious disease
were sufficiently treated with antibiotics. An example
of such an indicator is the proportion of patients with
acute tonsillitis and a positive Strep A test treated with
antibiotics (Table 2). For this group of QIs, a high value
is associated with a high quality of antibiotic
prescribing.
Table 1. Overview of quality indicators.
Type of infection
Quality indicators concerning
the diagnostic process
(n¼ 7, 6%)
Quality indicators concerning
the decision to prescribe anti-
biotics (n¼ 29, 22%)
Quality indicators concerning
the choice of antibiotics
(n¼ 94, 72%)
In total
(n¼ 130, 100%)
Respiratory tract infection 0 23 45 68
Urogenital infection 7 3 5 15
Skin infection 0 0 3 3
Eye infection 0 0 2 2
Unspecific 0 3 39 42
Respiratory tract infection: sore throat/tonsillitis, otitis externa, acute otitis media, acute rhinosinusitis, acute cough, bronchitis, pneumonia, chronic obstruct-
ive pulmonary disease exacerbation. Urogenital infection: urinary tract infections, sexually transmitted disease.
Table 2. Quality indicators focusing on the decision to prescribe antibiotics.
Type of infection Target for quality assessment: decision to prescribe antibiotics
Acute tonsillitis/pharyngitis Proportion treated with antibiotics [36]
Proportion with a positive Strep A test treated with antibiotics [36]
Proportion >1 year treated with antibiotics [35]
Acute otitis media Proportion treated with antibiotics [36]
Proportion <2 years treated with antibiotics [36]
Proportion >2 years treated with antibiotics [35]
Proportion >2 years with less than three days of symptoms treated with antibiotics [36]
Acute/chronic rhinosinusitis Proportion treated with antibiotics [36]
Proportion >18 years treated with antibiotics [35]
Acute bronchitis/bronchiolitis Proportion treated with antibiotics [36]
Proportion aged between 18–75 years treated with antibiotics [35]
Pneumonia Proportion aged between 18–65 years treated with antibiotics [35]
Acute exacerbation of COPD Proportion treated with antibiotics [36]
Proportion not fulfilling all the Anthonisen criteria treated with antibiotics [36]
Acute respiratory tract infection Proportion treated with antibiotics [36]
Acute upper respiratory tract infection Proportion >1 year treated with antibiotics [35]
Acute lower respiratory tract infection Proportion treated with antibiotics [36]
Proportion with a C-reactive protein <20mg/l treated with antibiotics [36]
Acute urinary tract infection Proportion of female patients >18 years treated with antibiotics [35]
Unspecific Consumption of antibiotics expressed in DID [23]
Seasonal variation of the total antibiotic consumption [23]
Anthonisen criteria: increased dyspnoea, increased and purulent expectorate.
COPD: chronic obstructive pulmonary disease; Strep A: streptococcus A antigen; DID: defined daily doses (DDD) per 1000 inhabitants
per day. Seasonal variation: consumption in the winter quarters (October, December, January, March) compared with the summer
quarters (July, September, April, June) of a 1-year period starting in July and ending the next calendar year in June, expressed as per-
centage: [DDD (winter quarters)/DDD (summer quarters) 1] 100.
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Table 3 shows QIs focusing on the choice of antibi-
otics. The majority of these QIs concerned RTIs (n¼ 45)
or were not related to a specific infection, so-called
drug-specific QIs (n¼ 39). In general, they assessed the
proportion of patients exposed to a specific subgroup
of antibiotics as a proportion of all patients treated
with antibiotics. Nearly, half of the QIs assessed the
proportion of patients treated with critically important
antibiotics of highest priority (CIA), as defined by
WHO.[22] The QIs focusing on the use of CIA included
quinolones (n¼ 22), cephalosporins (n¼ 10), and mac-
rolides (n¼ 8). Some QIs focused on the use of broad-
and narrow-spectrum penicillin, and one quality
indicator measured the seasonal variation for a specific
class of antibiotics (quinolones).[23] The majority of QIs
focusing on the choice of antibiotics were primarily
designed to assess overuse of antibiotics (i.e. high use
associated with a low quality) and only few were
designed to assess whether patients were sufficiently
treated with the drug of choice.
A full tabular summary of all QIs is available in the
online Supplementary Appendix 1.
Methods for development
A consensus method was used for the development
of all QIs included in this review. A consensus
method is a structured technique that seeks
consensus among a group of experts by synthesising
opinions.[24] Five studies developed QIs by means of
a modified Delphi technique involving repetitive
administration of anonymous questionnaires [25]
(Table 4). Three studies did not use the Delphi
method but developed QIs by means of other con-
sensus methods with a detailed description of how
consensus was obtained, typically involving one or
more meetings among the experts. Three studies did
not specify the consensus method used for the devel-
opment of QIs. Most expert panels consisted of GPs
and often also involved other specialists, such as clin-
ical microbiologists, clinical pharmacologists and
researchers in the area being investigated. The num-
ber of experts participating in the Delphi studies
ranged from nine to 305 and was generally higher
than the number of experts involved in the studies
not using the Delphi technique (range three to eight).
Nine studies based the development of QIs on a lit-
erature study and/or guidelines. Two studies used nei-
ther a literature study nor guidelines. Drug-specific
QIs for national application were mainly developed by
means of a non-Delphi technique, whereas studies
using the Delphi technique predominantly developed
disease-specific QIs for international application. Five
studies, all developing QIs for national application,
[26–30] were designed in a way that the QIs could
be applied to data from specific databases.
Table 3. Quality indicators focusing on the choice of antibiotics.
Type of infection Target for quality assessment: the choice of antibiotics
Acute tonsillitis/pharyngitis Proportion treated with a specific antibiotic (narrow-spectrum penicillin, macrolides, cephalosporins, broad-spec-
trum penicillin ± clavulanic acid) [36]
Proportion >1 year treated with a specific antibiotic (beta-lactamase sensitive penicillins, quinolones) [35]
Acute otitis media Proportion treated with a specific antibiotic (narrow-spectrum penicillin, broad-spectrum penicillin ± clavulanic
acid, macrolides, cephalosporins, quinolones) [36]
Proportion >2 years treated with a specific antibiotic (beta-lactamase sensitive penicillins, penicillins with
extended spectrum, quinolones) [35]
Acute/chronic rhinosinusitis Proportion treated with a specific antibiotic (narrow-spectrum penicillin, broad-spectrum penicillin ± clavulanic
acid, macrolides, cephalosporins, quinolones) [36]
Proportion >18 years treated with a specific antibiotic (beta-lactamase sensitive penicillins, penicillins with
extended spectrum, quinolones) [35]
Acute bronchitis/bronchiolitis Proportion aged between 18–75 years treated with a specific antibiotic (penicillins with extended spectrum, tetra-
cyclines, quinolones) [35]
Pneumonia Proportion treated with a specific antibiotic (narrow-spectrum penicillin, broad-spectrum penicillin ± clavulanic
acid, macrolides, cephalosporins, quinolones) [36]
Proportion aged between 18–65 years treated with a specific antibiotic (penicillins with extended spectrum, tetra-
cyclines, quinolones) [35]
Acute exacerbation of COPD Proportion treated with a specific antibiotic (broad-spectrum penicillin ± clavulanic acid, macrolides, cephalospor-
ins) [36]
Acute RTI Proportion with no history of penicillin allergy treated with a specific antibiotic (macrolides) [36]
Acute upper RTI Proportion >1 year treated with a specific antibiotic (beta-lactamase sensitive penicillins, quinolones) [35]
Acute lower RTI Proportion treated with a specific antibiotic (narrow-spectrum penicillin, broad-spectrum penicillin ± clavulanic
acid, macrolides, cephalosporins, quinolones) [36]
Urinary tract infection Proportion of female patients >18 years treated with a specific antibiotic (nitrofuran derivatives, trimethoprim
and derivatives, quinolones, other antibiotics) [35]
Unspecific Consumption of a specific antibiotic (macrolides, lincosamides, streptogramins, penicillins, cephalosporins, quino-
lones) expressed in DID [23]
DID: defined daily doses (DDD) per 1000 inhabitants per day.
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Discussion
Main findings
This review identified 130 QIs for diagnosis and anti-
biotic treatment of infectious diseases in primary care.
Most of the indicators concerned RTIs, or were not
related to a specific diagnosis. The majority (72%) of
the identified QIs focused on the choice of antibiotics,
22% on the decision regarding antibiotic prescription
and only 6% focused on the quality of the diagnostic
process. None of the diagnostic indicators focused on
RTIs or urinary tract infections, which are the most fre-
quent types of infections in primary care. Some indica-
tors were restricted to subgroups of patients specified
by age, specific symptoms, duration of symptoms and
the result of a point-of-care test. Other QIs focused on
the use of CIA such as quinolones, cephalosporins and
macrolides. All QIs were developed by means of a con-
sensus method, five of the eleven studies using the
Delphi technique.
Strengths and limitations
To our knowledge, this is the first systematic review
identifying QIs for diagnosis and antibiotic treatment
of infectious diseases in primary care. The number of
relevant studies was surprisingly low, considering the
large number of patients with various infections
attending primary care. Our review may have failed
to include some potentially relevant studies due to
language restrictions, and one also needs to acknow-
ledge the risk of publication bias. During the study
period, we became aware of a number of unpub-
lished or non-peer-reviewed QIs. We chose not to
include these indicators, since their development was
not well described. Several of these indicators con-
cerned the diagnostic process. This might indicate
that the need for this type of indicator exists, but
may be more difficult to develop, probably because
of different settings and recommendations that all
need to be taken into account when designing this
type of indicators.
Table 4. Methods for development.
Consensus methods Author, year Evidence base Expert panel Specification Application
Modified Delphi technique
Campbell, 2000 [29] Previous studies Pharmaceutical/medical advisers
(n¼ 305, 1. round)
Lead prescribing advisers
(n¼ 99, 2. round)
Drug-specific QIs National (UK)
Asch, 2002 [21] Literature study, national
guidelines
Primary care practitioners, STD
practitioners, medical direc-
tors (n¼ 9)
Disease-specific QIs National (US)
Coenen, 2007 [23] Literature guidelines Members of EuroDURG, GRIN/
ESPRIT, ESAC, WHO, BAPCOC
(n¼ 22)
Drug-specific QIs International
Hansen, 2010 [36] Literature study, national
guideliende
GPs, clinical microbiologists,
clinical pharmacologists from
13 countries (n¼ 27)
Disease-specific QIs International
Adriaenssens, 2011 [35] National guidelines GPs, specialists in infectious dis-
eases, microbiology, phar-
macy, pharmaco-
epidemiology, quality indica-
tor development and drug
utilization (n¼ 62)
Disease-specific QIs International
Non-Delphi specified
Bateman, 1996 [30] National guidelines GPs (n¼ 8) Drug-specific QIs National (ES)
Robertson, 2002 [28] Prescribing data GPs, specialist physicians, clin-
ical pharmacologists, phar-
macists, drug utilisation
experts (n¼not available)
Drug-specific QIs National (AU)
Giesen, 2007 [42] National guidelines GPs (n¼ 6, 1. round) (n¼ 7, 2.
round) (n¼ 4, 3. round)
Disease-specific QIs National (NL)
Non-Delphi unspecifieda
Van Roosmalen, 2007 [43] National guidelines Data not available Disease-specific QIs National (NL)
Fernandez, 2008 [27] National guidelines GPs, specialists, primary care
pharmacists, hospital phar-
macists (n ¼ not available)
Drug-specific QIs National (ES)
Pulcini, 2013 [26] Literature study, inter-
national guidelines
Infectious disease specialist,
public health specialist,
economist (n¼ 3)
Drug-specific QIs National (F)
aThe consensus method is not specified.
QIs: Quality indicators; GPs: general practitioners; STD: sexually transmitted diseases; BNF: British national formulary; GRIN: General Practice Respiratory
Infections Network; EuroDURG: European Drug Utilisation Research Group; ESPRIT: Study Group on Primary Care Topics; BAPCOC: Belgian Antibiotic Policy
Coordination Committee; ESAC: European Surveillance of Antimicrobial Consumption.
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The purpose of developing and using QIs varies,
depending on the audience. A clinician is interested in
the QIs that can easily measure the quality of his own
work. Contrary, a researcher (or perhaps a politician)
are possibly more interested in how the QIs were
developed and how they can be applied to various
sorts of data. However, the aim of this review was to
identify the existing QIs for diagnosis and antibiotic
treatment of infectious diseases and to inform the
readers about the various methods used for develop-
ment of QIs.
Comparison with relevant literature
Concerning patients with infectious diseases, one of
the most important decisions for the GPs to take is
whether to prescribe antibiotics or not. However, a
rational decision concerning prescribing depends on a
proper diagnosis. Thus, it seems particularly important
that the quality assurance includes the diagnostic
process.
The diagnostic process in primary care settings can
be challenging. It is often based on symptoms and
signs that have a low predictive value.[31] Studies
have shown that only about half of patients with typ-
ical symptoms of urinary tract infections have signifi-
cant bacteriuria,[32] and in patients with symptoms of
pneumonia, only the minority can be confirmed by
radiography.[33] Therefore, supplementary investiga-
tions or tests may be helpful to ensure a correct
diagnosis.
In several countries, point-of-care tests are recom-
mended in primary care in order to guide the GPs to
take a rational decision about antibiotic prescribing. In
the Nordic countries, for example, Strep A test and
CRP test are widely used for testing patients with sus-
pected RTIs. A newly published Cochrane review found
that the use of CRP tests can reduce antibiotic use in
patients with RTIs without harming the patients.[34]
Interestingly, we identified only very few QIs that
focused on the use of point-of-care tests.
Several studies aimed to develop QIs for inter-
national use.[23,35,36] However, these QIs can be diffi-
cult to apply to a national setting, as GPs may prefer
QIs that fit into their local setting. Thus, Hansen et al.
found that a set of internationally developed QIs were
not rated suitable as an assessment tool by a group of
Danish GPs.[37] Recommendations for diagnosis and
antibiotic treatment of infectious diseases vary consid-
erably between countries, and sometimes even within
the same country. The lack of similarity between rec-
ommendations challenges the development of QIs in
this area. However, initiatives have been taken to
standardise recommendations for the diagnosis and
treatment of a few infectious diseases on a European
level, for example the European Position Paper on
Rhinosinusitis and Nasal Polyps.[38]
Several indicators concerning choice of antibiotics
focused on the use of CIA such as quinolones, cephalo-
sporins, and macrolides. These antibiotics are especially
important in the treatment of serious infections and
are known to select for resistant bacteria.[22] The use
of specific types of antibiotics differs substantially
between countries.[39] Consequently, not all indicators
are relevant for evaluating the quality of antibiotic use
in all countries.[37]
We identified 42 QIs not related to a specific diag-
nosis. Politicians and health economists often use
these drug-specific QIs as an instrument to survey anti-
biotic use and compare antibiotic use on a general
level between regions and even countries. In most
countries, prescribing information is obtained from
health insurance and prescription databases containing
data with no information on the indication for the pre-
scription. Disease-specific QIs cannot be applied to this
type of data, and therefore, drug-specific QIs are more
frequently used.[23,27–30,40]
However, drug-specific QIs provide us with a black-
and-white simplification of the quality of prescribing
and may not be useful for the individual prescriber.[23]
The benefit of QIs comes from the debate associated
with the results and, hopefully, the debate can help
GPs optimise their antibiotic treatment of patients with
various infectious diseases. Most of the drug-specific
QIs were designed as they could be applied to data
from specific databases. This is probably a result of the
limited data availability in many countries. However, by
prioritising feasibility, the QIs have a narrow focus,
allowing only limited assessment and the validity of
the indicator might become more questionable.[29] In
countries with no diagnose-based databases, the use
of audit interventions in general practice makes it
possible to apply QIs on data with information on the
indication for the prescription.[41]
Several of the studies included in this review used
the Delphi technique to develop QIs. This method is
widely used in the prescribing research, and it is effect-
ive since the group of experts can be consulted from
geographically dispersed areas, although different
viewpoints cannot be debated face to face. Another
consensus method, The RAND method, has been
described as the only systematic method of combining
expert opinion and evidence. In the RAND appropriate-
ness method, experts are asked to rate predetermined
statements, meet for discussion, and then re-rate
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statements. None of the studies included in this review
used the RAND method.
The diversity of the number of experts in the
panel was large. Using many experts could indicate a
very careful approach, but when face-to-face meetings
are incorporated in the method, the sample should
not exceed 12 in order to facilitate group discussion
and prevent the group becoming too unwieldy.[25]
Achieving consensus by means of postal question-
naires allow participation of a large group of experts,
which most likely explains the generally higher num-
ber of experts in the studies using the Delphi tech-
nique. Scientific evidence for developing QIs is often
limited. Instead consensus techniques are used, which
systematically combine evidence and expert opinion
allowing a broader range of aspects of health care to
be assessed.[18,24] If possible, experts will be pro-
vided with the most updated evidence for the spe-
cific topic (e.g. national guidelines) and are
encouraged to relate this information to their opin-
ions. The majority of the studies included in this
review used guidelines and/or literature review as a
scientific base for the development of the QIs. Only
two studies based the development of QIs solely on
expert opinion and experience.
Conclusion
Despite infections being a frequent reason for
encounter in primary care, only few QIs for infectious
diseases were identified by this review. The remark-
ably small amount of existing QIs in this area should
encourage future development of new QIs. We
believe that it is a drawback that the QIs almost only
assess easily measurable aspects of care and fail to
encompass the more subjective aspects within the
diagnostic process. In order to include the diagnostic
process in quality assessment, national disease-specific
QIs taking specific local conditions into account are
needed.
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